Semaglutide Before and After: What the Clinical Evidence Actually Shows
When you search for "semaglutide before and after," you are usually looking for one thing: proof that this medication works, and a realistic sense of what it might do for you.
In this article
*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide is not FDA-approved. All clinical data cited reflects research using FDA-approved formulations; results with compounded semaglutide may differ. Individual results vary significantly. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*
---
When you search for "semaglutide before and after," you are usually looking for one thing: proof that this medication works, and a realistic sense of what it might do for you.
The photos and testimonials you find online are real experiences from real people. But they leave out something important: the full clinical picture. The scale tells one part of the story. Blood pressure, waist circumference, blood sugar, and cardiovascular risk tell the rest.
This article covers what the large clinical trials actually measured before and after treatment, the timeline of when those changes appear, and the factors that shape how different your results might look from anyone else's. The goal is to give you an accurate picture, not an aspirational one.
---
How Clinical Trials Define "Before and After"
In everyday conversation, "before and after" usually means photos or a number on the scale. In clinical research, it means something more precise: a set of measurements taken at baseline (before starting medication) and at defined intervals throughout treatment.
The STEP 1 trial, published in the New England Journal of Medicine in 2021, is the most widely cited study on semaglutide for weight management. [1] It enrolled 1,961 adults with obesity or overweight (without type 2 diabetes) and ran for 68 weeks. Participants received either once-weekly semaglutide 2.4 mg or a placebo, alongside lifestyle counseling. Researchers measured body weight, waist circumference, blood pressure, lipid levels, HbA1c, and quality of life at multiple points throughout the trial.
The picture that emerges from those measurements is considerably more complete than any single before-and-after photo.
---
Weight Outcomes: What the Numbers Show
The headline result from the STEP 1 trial is that participants receiving semaglutide 2.4 mg achieved a mean reduction of 14.9% of their body weight from baseline at 68 weeks, compared to 2.4% in the placebo group. [1]
A few things are worth understanding about that number.
First, 68 weeks is not a short course of treatment. It is just over sixteen months. The full weight loss trajectory built gradually across that entire period, with most of the accumulation happening between months three and twelve. Expecting equivalent results at eight weeks misreads how the medication works.
Second, 14.9% is a mean, which means it sits at the center of a wide distribution. Some participants lost substantially more. Others lost less. Individual variation in response to semaglutide is real and meaningful, not a flaw in the data.
Third, the 2.4 mg dose used in the trial is reached through a gradual titration schedule. Most programs begin at 0.25 mg per week and increase in steps over several months. The full appetite-suppressing effect accumulates as the dose increases, which is why results at twelve weeks look different from results at sixty-eight weeks.
The STEP 5 trial extended the observation period to two years. [2] Participants receiving semaglutide 2.4 mg achieved a mean reduction of 15.2% of body weight at 104 weeks. Weight loss continued to consolidate through the first year and remained largely stable through year two with continued treatment, reinforcing that this is a long-term intervention rather than a short-term fix.
---
---
Beyond the Scale: What Else Changes
Weight is the most visible before-and-after marker, but it is not the only one that matters clinically. The STEP 1 trial measured several other outcomes that tell a more complete story about what semaglutide does to the body.
Waist Circumference
Participants receiving semaglutide experienced a mean reduction in waist circumference of 13.54 cm from baseline at 68 weeks, compared to 4.13 cm in the placebo group. [1] Waist circumference is a meaningful clinical marker because abdominal fat (particularly visceral fat surrounding internal organs) is more closely associated with metabolic disease than total body weight alone.
Blood Pressure
Systolic blood pressure decreased by a mean of 6.16 mmHg in the semaglutide group versus 1.06 mmHg in the placebo group. [1] Diastolic blood pressure also improved, though by a smaller margin. These changes appear to occur partly through weight loss and partly through direct effects on the cardiovascular system, a distinction that has clinical implications for people managing hypertension.
Blood Sugar
Participants without diabetes at baseline still showed improvements in blood glucose markers. Fasting glucose and HbA1c decreased in the semaglutide group, and the rate of progression to prediabetes or type 2 diabetes was lower compared to placebo. [1] For people at elevated metabolic risk, these changes represent a meaningful shift in long-term health trajectory.
Lipid Profile
Total cholesterol, LDL cholesterol, and triglycerides all showed improvements in the semaglutide group, consistent with the metabolic benefits associated with significant weight loss and GLP-1 receptor agonism. [1]
Quality of Life
Participants receiving semaglutide reported greater improvements in health-related quality of life than the placebo group, including measures related to physical functioning, mental health, and overall wellbeing. [1] Weight loss alone does not fully account for these improvements, which suggests that appetite normalization and metabolic stabilization contribute to how people feel beyond what the scale reflects.
---
The Timeline: When Do These Changes Appear?
The clinical changes associated with semaglutide do not all arrive on the same schedule.
Weeks 1 to 4 are primarily a tolerance phase. The starting dose of 0.25 mg per week is not a therapeutic dose. Its purpose is to let your body adjust before increasing. Most people notice subtle shifts in appetite, but measurable weight change in this window is modest. GI side effects (nausea, mild bloating, changes in digestion) are most common here.
Weeks 4 to 12 bring dose increases and more consistent appetite suppression. Many people notice meaningful changes in how hungry they feel between meals and how much they want to eat at meals. Weight loss begins to accumulate more steadily. Blood pressure and blood sugar improvements often start appearing in this window as well.
Weeks 12 to 24 represent the period where many of the metabolic before-and-after changes become measurable. Waist circumference is often visibly reduced. Lab values, if checked at the three-month mark, typically reflect improvements in glucose and lipid markers.
Weeks 24 to 68 are where the full trajectory of results develops. The STEP 1 trial data shows that weight loss continues to build through most of this period, with the rate of change slowing as participants approach their nadir. Cardiovascular and metabolic improvements generally track with the weight trajectory.
---
Cardiovascular Before and After: The SELECT Trial
The most comprehensive look at semaglutide's long-term cardiovascular effects comes from the SELECT trial, published in the New England Journal of Medicine in 2023. [3] The trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity (without type 2 diabetes) and followed participants for a mean of 3.3 years.
The primary cardiovascular outcome (a composite of heart attack, stroke, and cardiovascular death) was reduced by 20% in the semaglutide group compared to placebo. [3] This cardiovascular benefit was observed independently of how much weight participants lost, suggesting that semaglutide has direct effects on the cardiovascular system beyond what weight reduction alone would explain.
For someone starting semaglutide today, the SELECT trial's "before and after" is measured in years rather than months, and in terms of major health events rather than pounds. It is a different kind of result than a transformation photo. It is also a clinically meaningful one.
---
Why Your Results Will Look Different
The clinical trial data gives you a population-level picture. Your individual before and after will be shaped by several factors that the averages cannot capture.
Starting weight and metabolic health. People with higher baseline weights often achieve larger absolute changes in body weight, though percentage reduction varies across different starting points and metabolic profiles.
Dose and titration schedule. Most people do not reach the 2.4 mg dose used in the STEP 1 trial without going through a multi-month titration. How quickly you move through that schedule, and how high your final dose goes, meaningfully affects your results.
Dietary choices. Semaglutide reduces appetite. What you eat within that reduced appetite window still matters. Adequate protein intake supports the preservation of lean muscle mass during weight loss, which affects body composition outcomes and long-term metabolic health.
Physical activity. Exercise does not dramatically accelerate weight loss on its own, but resistance training in particular helps preserve muscle mass during caloric restriction. Body composition (ratio of fat to muscle) is a meaningful clinical marker that body weight alone does not reflect.
Individual biological variation. Genetics, gut microbiome composition, baseline hormone levels, and other factors influence how any given person responds to GLP-1 receptor agonists. Two people with nearly identical profiles can have meaningfully different outcomes on the same dose.
Consistency. The clinical trials involved close protocol adherence. Real-world results depend heavily on consistency with the weekly injection schedule, provider follow-up, and lifestyle habits.
---
How to Think About Your Own Before and After
If you are starting semaglutide or considering it, the most useful before-and-after framework is not a single number on a scale. It is a set of baseline measurements that you can track over time with your provider.
Worth measuring at baseline and at intervals:
- Body weight
- Waist circumference (often more meaningful than weight alone)
- Blood pressure
- Fasting glucose and HbA1c
- Fasting lipid panel (cholesterol, triglycerides)
- How you feel physically and mentally
Your provider can also help you interpret your results in context: whether a given change is on track, what it suggests about your response to the medication, and whether any adjustments are warranted.
---
---
What Compounded Semaglutide Means for These Numbers
The clinical data cited throughout this article was generated using FDA-approved semaglutide formulations (Wegovy and Ozempic) in controlled trial settings. Prescriva and other telehealth providers offer compounded semaglutide, which is prepared by licensed 503A compounding pharmacies.
Compounded semaglutide is not FDA-approved and has not been studied in the same large-scale trials as the branded formulations. It is prepared by licensed 503A pharmacies as a patient-specific formulation; it is not a generic, and it has not undergone the FDA approval process applied to Wegovy or Ozempic. The specific outcome data from the STEP and SELECT trials applies to FDA-approved formulations only, and your results with a compounded formulation may differ.
This does not mean compounded semaglutide is ineffective or unsafe, but it does mean that the evidence base for the specific numbers cited above comes from a different product than what most telehealth platforms dispense. Your provider can explain what this means for your specific situation.
---
Working With Your Provider
The most accurate before-and-after story for your own experience is one that unfolds under clinical supervision.
Your provider should be reviewing your progress at regular intervals, monitoring for side effects, adjusting your dose based on your response and tolerability, and helping you interpret what your results mean for your long-term health. A program that is simply a monthly prescription with no follow-up does not serve you as well as one with structured check-ins.
If you are considering starting semaglutide and want to understand what a medically supervised program looks like, a licensed provider is the right starting point.
---
*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. All clinical data cited reflects FDA-approved formulations; results with compounded semaglutide may differ. Individual results vary significantly based on dose, lifestyle, and individual physiology. Prescriva services are provided through Prescriva LLC, doing business as Prescriva, a Management Services Organization. Consult your licensed healthcare provider before starting or adjusting any medication.*
---
References
- [Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
- [Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945/)
- [Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)
Stay informed
Weekly research updates and health guides. No spam.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185. Published Research (2021).
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID 36216945. Published Research (2022).
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID 37952131. Published Research (2023).
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →
